ReviewInfectious diseases of poverty2016
Critical analysis of molluscicide application in schistosomiasis control programs in Brazil.
Review in Infectious diseases of poverty, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 84 citations in OpenAlex.
- The effectiveness of water treatment processes against schistosome cercariae: A systematic review.PLoS neglected tropical diseases · 2018Pooled it
- Ecological environmental management program promotes Schistosomiasis control in Erhai Lake of China: an analysis based on SWOT-ANP-ADAM approach.Infectious diseases of poverty · 2026Article
- Water, sanitation, and hygiene in schistosomiasis control: A scoping review of evidence gaps across transmission pathways.PLOS global public health · 2026Article
- Development of a spirulina feed effective only for the two larval stages of Schistosoma mansoni, not the intermediate host mollusc.Tropical medicine and health · 2025Article
- Molluscicidal and Schistosomicidal Activities of 2-(1Pharmaceuticals (Basel, Switzerland) · 2025Article
- Acute and sub-acute toxicity of ethanol extracts of Hagenia abyssinica and Rumex abyssinicus flowers in Swiss albino mice.PloS one · 2025Article
- Symbiotic bacteria associated with entomopathogenic nematodes showed molluscicidal activity against Biomphalaria glabrata, an intermediate host of Schistosoma mansoni.Parasites & vectors · 2024Article
- Molluscicidal activity of sodium hypochlorite againstParasite epidemiology and control · 2023Article
- Status Quo and Future Perspectives of Molecular and Genomic Studies on the GenusInternational journal of molecular sciences · 2023Review
- Survey on Limnic Gastropods: Relationships between Human Health and Conservation.Pathogens (Basel, Switzerland) · 2022Article
- Effect ofMolecules (Basel, Switzerland) · 2022Article
- Transmission potential of human schistosomes can be driven by resource competition among snail intermediate hosts.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Impact of the coronavirus disease 2019 lockdown on Schistosoma host Oncomelania hupensis density in Wuhan.Acta tropica · 2022Article
- Current Status for Controlling the Overlooked Caprine Fasciolosis.Animals : an open access journal from MDPI · 2021Review
- Interventions can shift the thermal optimum for parasitic disease transmission.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Afforestation suppresses Oncomelania hupensis snail density through influencing algae in beaches of the Dongting Lake.PLoS neglected tropical diseases · 2021Article
- Article
- Molecular Characterization of Rotifers and Their Potential Use in the Biological Control ofFrontiers in cellular and infection microbiology · 2021Article
- Assessing the role of Filopaludina martensi martensi as a biocontrol agent of Bithynia siamensis goniomphalos, the first intermediate host of Opisthorchis viverrini.Parasitology research · 2020Article
- Molluscicidal and parasiticidal activities of Eryngium triquetrum essential oil on Schistosoma mansoni and its intermediate snail host Biomphalaria glabrata, a double impact.Parasites & vectors · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Brazil, Biomphalaria glabrata, B. tenagophila, and B. straminea are naturally infected by the trematode Schistosoma mansoni, the causative agent of schistosomiasis. Despite decades of governmental efforts through official control programs, schistosomiasis remains an important public health problem in the country: thousands of people are infected with the trematode each year and millions live in endemic areas. The World Health Organization recommends using a combination of molluscicide (niclosamide) and mass chemotherapy to control the transmission of schistosomiasis, with this treatment successfully reducing the morbidity of the disease. In the past, niclosamide has been used in official schistosomiasis control programs in Brazil. However, as B. glabrata recolonizes even after molluscicide application, the use of molluscicides has gradually decreased in the country until they were discontinued in 2002, mainly due to the rising global pressure to preserve the environment and the difficulties of obtaining licenses from the Brazilian Ministry of Environment to use toxic substances in aquatic ecosystems. Therefore, the discovery of new molluscicides, which could be more selective to Biomphalaria species and less harmful to the aquatic ecosystem, is necessary. In addition, political efforts to sensitize funders to provide grants for this field of research are required. In this context, this article aims to make a critical analysis of molluscicide application in schistosomiasis control programs in Brazil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.